MTOR and Hepatic steatosis: The use of specifically pharmacological inhibitor of mTOR, such as rapamycin (RAPA) as approved by the United States Food and Drug Administration (FDA) (Flaxman et al., 2019), has become the standard of care for improving fatty liver condition in alcoholic and non-alcoholic fatty liver diseases via reducing lipid synthesis or promoting lipid oxidation (Lin et al., 2013).